iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

The VanEck Biotech ETF (BBH) was launched on December 20, 2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.

On November 3, 2025, Privium Fund Management B.V. reported selling 138,263 shares of Arrowhead Pharmaceuticals ( ARWR 1.57%) ...

This ETF may offer you the best return if you commit to it for the long term. Stock picking is a fantastic way to build ...

Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The ...

Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment ...

Discover key Royalty Pharma Q3 2025 earnings insights—double-digit growth, new acquisitions, and raised guidance for investors.

Stocks to Buy and Sell. Biotechnology ETF (NASDAQ:IBB) is one of the trending analyst calls. Jason Snipe, Founder and CIO of ...

The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in ...